AskVantage

Biotech and enhanced humans

New gene therapy technique cures deafness in mice

Millions of people around the world suffer from deafness, now scientists might be zero'ing in on a new cure that could change their lives forever

Key takeaways

  • In 2015, a team at Boston Children's Hospital (BCH) and Harvard Medical School (HMS) reported restoring the hearing in genetically deaf mice using gene therapy.
  • Margaret Kenna, MD, MPH, a specialist in genetic hearing loss at BCH who does research on Usher syndrome, is excited about the work.
Cite or link to this article

Griffin, M. (2017) 'New gene therapy technique cures deafness in mice', 311 Institute, 8 February. Available at: https://www.311institute.com/new-gene-therapy-technique-cures-deafness-in-mice/ (Accessed: 1 October 2026).

In 2015, a team at Boston Children's Hospital (BCH) and Harvard Medical School (HMS) reported restoring the hearing in genetically deaf mice using gene therapy. Now the Boston Children's research team reports restoring a much higher level of hearing, down to 25 decibels, which is the equivalent of a whisper, using an improved gene therapy vector developed at HMS' Massachusetts Eye and Ear (MEE) laboratory.

While previous gene therapy treatments have only been able to penetrate the cochlea's inner hair cells they showed that one treatment technique, called Anc80, that used synthetic genes, was able to safely transfer genes to the hard to reach outer hair cells of the ear.

"We have shown that Anc80 works remarkably well in terms of infecting cells of interest within the inner ear," said Konstantina Stankovic, an Otologic Surgeon at MEE and associate professor of Otolaryngology at HMS, "with more than 100 genes already known to cause deafness in humans, there are many patients who may eventually benefit from this technology."

In the latest study, led by Gwenaëlle Géléoc, PhD, of the Department of Otolaryngology at BCH, studied mice with a mutation in Ush1c, the same mutation that causes Usher type 1c deafness, as well as a loss of balance, in humans. The mutation causes a protein called harmonin to switch off, and as a result the sensory hair cell bundles in the ear responsible for receiving sound and signalling the brain deteriorate and become disorganised, causing profound hearing loss.

In the latest trials when the teams used Anc80 to deliver a new, corrected Ush1c gene into the inner ears of the mice, the inner and outer hair cells in the cochlea began to produce normal full-length harmonin and the hair cells formed normal, organised bundles that responded to sound waves and signalled the brain, restoring the mice's hearing.

"The latest treatment is the most effective one we've tested," Géléoc says, "outer hair cells amplify sound, allowing inner hair cells to send a stronger signal to the brain. We now have a system that works well and rescues auditory and vestibular function to a level that's never been achieved before."

Most importantly, deaf mice treated soon after birth also began to hear. Géléoc and colleagues showed this first in a "startle box," which detects whether a mouse jumps in response to sudden loud sounds. When they next measured responses in the auditory regions of the brain, a more sensitive test, the mice responded to much quieter sounds, with 19 out of 25 mice hearing sounds quieter than 80 decibels, and a few could even hear sounds as soft as 25decibels, like normal mice.

"Now, you can whisper, and they can hear you," said Géléoc.

Margaret Kenna, MD, MPH, a specialist in genetic hearing loss at BCH who does research on Usher syndrome, is excited about the work.

"Anything that could stabilize or improve native hearing at an early age would give a huge boost to a child's ability to learn and use spoken language," she says, "cochlear implants are great, but your own hearing is better in terms of range of frequencies, nuance for hearing voices, music and background noise, and figuring out which direction a sound is coming from. In addition, the improvement in balance could translate to better and safer mobility for Usher Syndrome patients."

Since patients, and mice, with Usher 1c also have balance problems caused by hair-cell damage in the vestibular organs of the ear, the researchers also tested whether gene therapy restored balance and it did and the mice were able to stay on a rotating rod for longer periods without falling off.

While further work is needed before the technology can be brought to patients it's a promising start and one day, just as we've recently seen how gene therapy can cure blindness, now we might also see it cure deafness.

FAQ

Why does this matter?

Millions of people around the world suffer from deafness, now scientists might be zero'ing in on a new cure that could change their lives forever

Matthew Griffin

About the author

Matthew Griffin Founder, 311 Institute

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."

Read full bio

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.

An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.

As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.

What future do you need to see?

Choose one to get started on biotech and enhanced humans and the future of your organisation.

Where should Matthew reply?

Takes 30 seconds. No obligation. Matthew replies quickly. Privacy

Tag Cloud

Sources and further reading

  1. Boston Children's Hospital childrenshospital.org
  2. Harvard Medical School hms.harvard.edu
  3. Massachusetts Eye and Ear masseyeandear.org
  4. Usher 1C en.wikipedia.org

Source: first published by the 311 Institute on 8 February 2017. Cite as: Griffin, M. (2017). New gene therapy technique cures deafness in mice. 311 Institute. https://www.311institute.com/new-gene-therapy-technique-cures-deafness-in-mice/

You are welcome to quote this article with credit and a link to the original.

Book a Keynote